A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (KER-050-D301 (RENEW))

Principal Investigator

Dr Onima Chowdhury

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1010708